Date: Saturday, June 1, 2019
Session Time: 5:30pm-7:30pm
Presentation Time: 5:30pm-7:30pm
Location: Hall C & D
*Purpose: African American renal transplant recipients (RTR) exhibit more immunoreactivity to allografts which may contribute to chronic rejection. This study investigated race-sex influences on ex vivo immunoreactivity and the quantitative (cells/µl) and qualitative (HLADR expression) relationship to peripheral T regulatory cells(Tregs) and drug exposure in stable Caucasian and African American RTR receiving mycophenolic acid and tacrolimus minimization.
*Methods: Thirty-eight stable RTR greater than 1 yr post-transplant completed a 12-hour study with serial collections at trough, 4, 8 and 12 hours. The immune response potential was evaluated by interleukin-2 (IL-2) and Interferon gamma (IFN-Ɣ) production by CD3+CD4+ T cells after ex-vivo treatment with PMA/Ionomycin with Brefeldin-A. Peripheral Tregs: CD3+CD4+CD25+CD127- and the immunosuppressive potential (HLADR expression) were determined by flow cytometric immunophenotyping. Tacrolimus and mycophenolic acid area under the curve 0-12 hours(AUC0-12) were determined. Data was represented as AUC0-12 of Cell Sub-populations and drug exposure [Mean(SE)] and analyzed by univariate ANOVA.
*Results: Table 1 summarizes major findings. Tacrolimus and mycophenolic acid troughs were within the therapeutic range with no group differences. Tacrolimus AUC0-12 was higher in African Americans(P=0.025) with no group differences in mycophenolic acid AUC0-12. No correlations of ex vivo immunoreactivity with Tregs or immunosuppressive drug exposure were found.
*Conclusions: Increased IFN-Ɣ and L-2 from CD3+CD4+ T cells quantitated greater ex vivo immunoreactivity in African American male RTR with no relationship to Tregs or immunosuppressive drug exposure. These findings warrent additional investigation into disparity in race-sex immunoreactivity during tacrolimus minimization post-renal transplant.
|AUC Mean(SE)||Caucasian-Males||African American-Males||Caucasian-Females||African American- Females||Adjusted P|
|STIM CD3+CD4+ IFNg+IL-2- %GATE||0.09(0.02)||10.7(3.6)||0.49(0.47)||0.84(0.54)||0.036|
|STIM CD3+CD4+ IFNg-IL-2+ %GATE||1.66(0.30)||14.6(5)||2.32(0.61)||1.36(0.39)||0.09|
To cite this abstract in AMA style:Tornatore K, Attwood K, Venuto R, Minderman H. Race-Sex Effects on Immune Response Potential during Tacrolimus Minimization Therapy in Stable Renal Allograft Recipients [abstract]. Am J Transplant. 2019; 19 (suppl 3). https://atcmeetingabstracts.com/abstract/race-sex-effects-on-immune-response-potential-during-tacrolimus-minimization-therapy-in-stable-renal-allograft-recipients/. Accessed November 29, 2020.
« Back to 2019 American Transplant Congress